Tempus AI has expanded its collaboration with Merck and Moderna to support the potential commercialization of intismeran autogene, an individualized neoantigen therapy — in effect, a cancer vaccine custom-built from each patient’s own tumor DNA — that the two drugmakers have been developing together alongside Merck’s blockbuster immunotherapy Keytruda. Under the expanded deal, announced October 9, Tempus will supply the next-generation sequencing and sample-collection infrastructure needed to identify the mutations unique to a patient’s tumor, feeding Moderna’s mRNA manufacturing process that turns that genetic blueprint into a personalized vaccine. Tempus founder and CEO Eric Lefkofsky framed the expansion as evidence that sequencing is becoming inseparable from treatment itself, saying the company is building “real-world clinical and diagnostic infrastructure” rather than simply running a lab test.
From Lab Curiosity to Late-Stage Therapy
Individualized neoantigen therapies were, for most of the 2010s, a research curiosity — technically elegant but too slow and expensive to manufacture one vaccine per patient at any scale. Moderna and Merck’s mRNA-based approach, which uses tumor and normal-tissue sequencing to identify neoantigens unique to each patient’s cancer and then rapidly synthesizes a matching vaccine, began turning that into something closer to standard oncology practice after earlier-stage melanoma trials showed the combination with Keytruda could reduce recurrence or death compared with Keytruda alone. Those results propelled the program into a Phase 3 trial, and late-August data releases describing continued benefit for patients on the vaccine-plus-Keytruda arm sent Tempus shares up nearly 40% in a single week, according to market commentary at the time, even as the broader market slipped.
Tempus’s Specific Role — and Why Personalis Matters
Central to the expanded collaboration is Tempus’s pending acquisition of Personalis, a genomic diagnostics company whose NeXT Platform performs the whole-exome and whole-transcriptome sequencing used to identify tumor neoantigens for the Merck-Moderna vaccine program. Tempus’s roughly $1.5 billion all-stock deal for Personalis, agreed earlier this year and expected to close in late 2026 or early 2027, effectively hands Tempus the sequencing backbone that already sits inside the vaccine’s development pipeline — a bet that as personalized cancer vaccines move toward approval and eventual commercial launch, whoever controls the sequencing workflow captures a recurring diagnostic revenue stream alongside any therapeutic royalties.
The Case for Optimism
Oncologists who have watched checkpoint inhibitors like Keytruda plateau in effectiveness for many solid tumors see individualized neoantigen vaccines as one of the more credible next steps, precisely because they are matched to a specific patient’s mutational profile rather than targeting a single shared marker. Combining a personalized vaccine with an already-approved immunotherapy, rather than replacing it, lowers the regulatory and clinical bar compared with developing a stand-alone cancer vaccine, and gives Merck a mechanism to extend Keytruda’s commercial life as its patent exclusivity approaches expiration later this decade.
The Skeptics’ Case: Manufacturing, Cost and Access
Critics of the personalized-vaccine model point to the same problem that stalled it for over a decade: manufacturing a bespoke product for every patient, on a clock fast enough to matter for someone with aggressive cancer, is logistically and financially demanding in ways that off-the-shelf drugs are not. Even strong trial results do not resolve questions about whether health systems outside leading academic cancer centers can replicate the sequencing-to-manufacturing turnaround time, or whether insurers will reimburse a therapy whose price point is likely to run well above standard immunotherapy. There is also a narrower scientific caveat: Phase 3 benefit in one tumor type and patient population, such as high-risk resected melanoma, does not guarantee the same magnitude of benefit as the companies pursue additional cancer types, which the expanded Tempus collaboration is explicitly intended to support.
What’s Next
With Phase 3 melanoma data already filed and the companies reportedly working through regulatory discussions, the expanded Tempus partnership positions the sequencing giant as infrastructure for whatever comes next — additional tumor types, expanded trial sites, and eventually a commercial-scale version of a therapy that, if approved, would be among the first truly individualized cancer treatments to reach the market at any real volume. Investors have already priced in substantial optimism, as reflected in Tempus’s late-summer stock surge, but the harder test will be operational: whether Tempus, Personalis and Moderna can sequence, manufacture and ship a personalized vaccine fast enough, and cheaply enough, to make the model work beyond a clinical trial setting.
Photo: Tima Miroshnichenko / PEXELS via Pexels
